Neuropsychiatric comorbidities in Huntington’s and Parkinson’s Disease: A United States claims database analysis

Objective Huntington’s disease is a rare, genetic, neurodegenerative disease characterized by a triad of cognitive, behavioral, and motor symptoms. The condition gradually results in increasing disability, loss of independence, and ultimately death. Our objective was to use United States claims data...

Full description

Saved in:
Bibliographic Details
Published in:Annals of clinical and translational neurology Vol. 8; no. 1; pp. 126 - 137
Main Authors: Ishihara, Lianna, Oliveri, David, Wild, Edward J.
Format: Journal Article
Language:English
Published: United States John Wiley & Sons, Inc 01.01.2021
John Wiley and Sons Inc
Subjects:
Amyotrophic lateral sclerosis
Brain damage
Codes
Comorbidity
Databases, Factual
Dementia
Demographics
Disease
Health care
Humans
Huntington Disease - complications
Huntington Disease - psychology
Huntingtons disease
Medicaid
Mental Disorders - epidemiology
Parkinson Disease - complications
Parkinson Disease - psychology
Parkinson's disease
Population
Prevalence
Retrospective Studies
United States
United States
United States > US
ISSN:2328-9503, 2328-9503
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Huntington’s disease is a rare, genetic, neurodegenerative disease characterized by a triad of cognitive, behavioral, and motor symptoms. The condition gradually results in increasing disability, loss of independence, and ultimately death. Our objective was to use United States claims data (which offer valuable insight into the natural history of disease) to compare the prevalent comorbidities of people with Huntington’s disease against matched controls with Parkinson’s disease or with no major neurodegenerative diseases (general population controls). We also assess medication use in people with Huntington’s disease. Methods This was a retrospective, observational study using data from the IBM MarketScan® Databases. Cases and controls were matched 1:1, and comorbidities were analyzed in each group during 2017. Medications were also assessed in the Huntington’s disease cohort. Eligible cases had ≥ 2 diagnostic codes for Huntington’s disease; controls had ≥ 2 codes for Parkinson’s disease (with no record of Huntington’s disease), or, for general population controls, no record of Huntington’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, or dementia. Results A total of 587 matched individuals were assessed in each cohort. Depression and anxiety were more common in Huntington’s disease versus Parkinson’s disease (odds ratios: 1.51 and 1.16, respectively). Other conditions more common in Huntington’s disease included dementia, communication/speech problems, dysphagia, and falls. The use of antidepressant (59.9%) and antipsychotic (39.5%) medications was frequent among Huntington’s disease cases. Interpretation These data highlight the prevalence of psychiatric, cognitive, communication, swallowing, and mobility problems in people with Huntington’s disease, underscoring the need for holistic expert care of these individuals.
Bibliography:This study was funded by F. Hoffmann‐La Roche Ltd. Support for third‐party writing assistance for this article, provided by Sam Fraser, PhD and Danielle Sheard, BA (Costello Medical, Cambridge, UK)a, was funded by F. Hoffmann‐La Roche Ltd in accordance with Good Publication Practice (GPP3) guidelines
Funding Information
.
http://www.ismpp.org/gpp3
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
This study was funded by F. Hoffmann‐La Roche Ltd. Support for third‐party writing assistance for this article, provided by Sam Fraser, PhD and Danielle Sheard, BA (Costello Medical, Cambridge, UK)a, was funded by F. Hoffmann‐La Roche Ltd in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).
ISSN:2328-9503
2328-9503
DOI:10.1002/acn3.51252